company background image

BioventixAIM:BVXP Stock Report

Market Cap







27 Sep, 2021


Company Financials
BVXP fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance4/6
Financial Health6/6

BVXP Overview

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide.

Price History & Performance

Summary of all time highs, changes and price drops for Bioventix
Historical stock prices
Current Share PriceUK£39.75
52 Week HighUK£37.50
52 Week LowUK£45.49
1 Month Change-5.92%
3 Month Change-0.13%
1 Year Change-3.05%
3 Year Change25.00%
5 Year Change253.33%
Change since IPO1,938.46%

Recent News & Updates

Shareholder Returns

BVXPGB BiotechsGB Market

Return vs Industry: BVXP underperformed the UK Biotechs industry which returned 32% over the past year.

Return vs Market: BVXP underperformed the UK Market which returned 23.4% over the past year.

Price Volatility

Is BVXP's price volatile compared to industry and market?
BVXP volatility
BVXP Beta0.26
Industry Beta0.83
Market Beta1

Stable Share Price: BVXP is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: BVXP's weekly volatility (3%) has been stable over the past year.

About the Company

200312Peter Harrison

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services.

Bioventix Fundamentals Summary

How do Bioventix's earnings and revenue compare to its market cap?
BVXP fundamental statistics
Market CapUK£207.07m
Earnings (TTM)UK£6.87m
Revenue (TTM)UK£10.38m


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BVXP income statement (TTM)
Cost of RevenueUK£880.84k
Gross ProfitUK£9.50m

Last Reported Earnings

Dec 31, 2020

Next Earnings Date


Earnings per share (EPS)1.32
Gross Margin91.51%
Net Profit Margin66.22%
Debt/Equity Ratio0.0%

How did BVXP perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio


Is Bioventix undervalued compared to its fair value and its price relative to the market?


Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: BVXP (£39.75) is trading above our estimate of fair value (£26.75)

Significantly Below Fair Value: BVXP is trading above our estimate of fair value.

Price To Earnings Ratio

PE vs Industry: BVXP is good value based on its PE Ratio (30.1x) compared to the UK Biotechs industry average (69.7x).

PE vs Market: BVXP is poor value based on its PE Ratio (30.1x) compared to the UK market (23.4x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BVXP's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BVXP is overvalued based on its PB Ratio (20.1x) compared to the GB Biotechs industry average (5.8x).

Future Growth

How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bioventix has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Bioventix performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BVXP has high quality earnings.

Growing Profit Margin: BVXP's current net profit margins (66.2%) are higher than last year (65.3%).

Past Earnings Growth Analysis

Earnings Trend: BVXP's earnings have grown by 14.8% per year over the past 5 years.

Accelerating Growth: BVXP's earnings growth over the past year (5%) is below its 5-year average (14.8% per year).

Earnings vs Industry: BVXP earnings growth over the past year (5%) underperformed the Biotechs industry 19.9%.

Return on Equity

High ROE: BVXP's Return on Equity (66.7%) is considered outstanding.

Financial Health

How is Bioventix's financial position?

Financial Position Analysis

Short Term Liabilities: BVXP's short term assets (£9.8M) exceed its short term liabilities (£839.8K).

Long Term Liabilities: BVXP's short term assets (£9.8M) exceed its long term liabilities (£58.1K).

Debt to Equity History and Analysis

Debt Level: BVXP is debt free.

Reducing Debt: BVXP has not had any debt for past 5 years.

Debt Coverage: BVXP has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: BVXP has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet


What is Bioventix current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BVXP's dividend (3.55%) is higher than the bottom 25% of dividend payers in the UK market (1.34%).

High Dividend: BVXP's dividend (3.55%) is low compared to the top 25% of dividend payers in the UK market (3.93%).

Stability and Growth of Payments

Stable Dividend: BVXP's dividends per share have been stable in the past 10 years.

Growing Dividend: BVXP's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (71.9%), BVXP's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average board tenure


Peter Harrison (63 yo)

no data




Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a...

CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD389.26K) is below average for companies of similar size in the UK market ($USD559.09K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.

Board Members

Experienced Board: BVXP's board of directors are considered experienced (7.7 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Bioventix PLC's employee growth, exchange listings and data sources

Key Information

  • Name: Bioventix PLC
  • Ticker: BVXP
  • Exchange: AIM
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£207.071m
  • Shares outstanding: 5.21m
  • Website:

Number of Employees


  • Bioventix PLC
  • 27-28 Eastcastle Street
  • London
  • Greater London
  • W1W 8DH
  • United Kingdom


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 17:43
End of Day Share Price2021/09/27 00:00
Annual Earnings2020/06/30

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.